Seattle, November 19 (ots/PRNewswire)
- Cell Therapeutics, Inc.
(CTI) (Nasdaq: CTIC; Nuovo Mercato) today announced that it is
responding to inquiries from the U.S. Attorney for the Western
District of Washington in connection with previously disclosed
promotional practices for TRISENOX. CTI is fully cooperating with the
U.S. Attorney in this matter.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company
committed to developing an integrated portfolio of oncology products
aimed at making cancer more treatable. For additional information,
please visit www.cticseattle.com
This press release includes forward-looking statements that
involve a number of risks and uncertainties, the outcome of which
could materially and/or adversely affect actual future results.
Specifically, the forward-looking statements contained in this press
release include statements about risks and uncertainties that could
affect CTI's product TRISENOX(R). These risks include, but are not
limited to sales and marketing developments in the biopharmaceutical
industry in general and in particular including, without limitation,
determinations by regulatory and administrative governmental
authorities; and the risk factors listed or described from time to
time in the Company's filings with the Securities and Exchange
Commission including, without limitation, the Company's most recent
filings on Forms 10-K, 8-K, and 10-Q. CTI is under no obligation to
(and expressly disclaims any such obligation to) update or alter its
forward-looking statements whether as a result of new information,
future events, or otherwise.
Web site: http://www.cticseattle.com
ots Originaltext: CELL THERAPEUTICS, INC.
Im Internet recherchierbar: http://www.newsaktuell.ch
investors, Leah Grant, +1-206-282-7100, or fax, +1-206-272-4434, or
, or media, Susan Callahan, +1-206-272-4472, or
fax, +1-206-272-4434, or firstname.lastname@example.org
, both of Cell